Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor

Jelena Urosevic, James T. Lynch, Stefanie Meyer, Nevin Yusufova, Elizabeth Wiseman, Paul Waring, Ted Hong, Zuleyha Ozen, Haiyun Wang, Lauren Bradshaw, Hannah Tomczak, Ho Man Chan, Ruben Reyes, Susan Critchlow, Anas Younes, Emma Dean

Blood (2023) 142 (Supplement 1): 4185.

https://doi.org/10.1182/blood-2023-174445

Published: 2023

Journal Articles

Correlation Between Markers of Bone Turnover and Vitamin D Levels in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Brea C. Lipe, MD, Tara L. Lin, MD, Omar S. Aljitawi, MD, Abdulraheem Yacoub, MD, Ruben Reyes, MD, Suman Kambhampati, MD, Peter van Veldhuizen, MD, Joseph R. Mikhael, MD

Blood (2014) 124 (21): 3471.

https://doi.org/10.1182/blood.V124.21.3471.3471

Published: 2014

Journal Articles

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Sarit Assouline, Julie E. Chang, MD, Bruce D. Cheson, MD, Robert Rifkin, MD, Solomon Hamburg, MD, PhD, Ruben Reyes, MD, Ai-Min Hui, MD, PhD, Jiang Yu, Neeraj Gupta, PhD, Alessandra Di Bacco, PhD, Yaping Shou, Peter Martin, MD

Blood (2012) 120 (21): 3646.

https://doi.org/10.1182/blood.V120.21.3646.3646

Published: 2012

Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2611.

https://doi.org/10.1182/blood.V118.21.2611.2611

Published: 2011

Journal Articles

Results of a Phase I Open-Label Study of Decitabine in Combination with Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia,

Casey B Williams, Pharm.D., Suman Kambhampati, MD, Siddhartha Ganguly, MD, Omar S. Aljitawi, MD, Ruben Reyes, MD, Allan Fleming, MD, Kapil N. Bhalla, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO

Blood (2011) 118 (21): 3610.

https://doi.org/10.1182/blood.V118.21.3610.3610

Published: 2011

Journal Articles

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Rekha Rao, PhD, Kami Maddocks, MD, Amy J. Johnson, PhD, Lata Chauhan, PhD, Suman Kambhampati, MD, Siddhartha Ganguly, MD, Ruben Reyes, MD, Omar S. Aljitawi, MD, Kevin Schorno, MBA, Kendra Ford, MSN, RN, CCRC, Eileen Dickman, PhD, MBA, John C. Byrd, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 929.

https://doi.org/10.1182/blood.V118.21.929.929

Published: 2011

Journal Articles

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Ramesh Balusu, PhD, Josiah Cox, Stacey Hembruff, MS, Warren Fiskus, BSc, PhD, Rekha Rao, PhD, Uma Mudunuru, MS, Ruben Reyes, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Heather Male, MD, Allan Fleming, MD, Casey B Williams, Pharm.D., Joseph McGuirk, DO, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 733.

https://doi.org/10.1182/blood.V118.21.733.733

Published: 2011

Journal Articles

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Warren Fiskus, PhD, Jacqueline Smith, MS, Uma Mudunuru, MS, Stacey Hembruff, MS, Ruben Reyes, MD, Sunil Abhyankar, MD, Joseph McGuirk, DO, Omar S. Aljitawi, MD, Siddhartha Ganguly, MD, Stephen K. Horrigan, PhD, Sunil Sharma, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 65.

https://doi.org/10.1182/blood.V118.21.65.65

Published: 2011

NARROW

Epigenetic Silencing of MTAP in Hodgkin's Lymphoma Renders It Sensitive to a 2 nd Generation PRMT5 Inhibitor

Correlation Between Markers of Bone Turnover and Vitamin D Levels in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Results of a Phase I Open-Label Study of Decitabine in Combination with Midostaurin (PKC412) for Elderly (Age ≥ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia,

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Treatment with β-Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only